Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 7/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253922 | 1.00 | SUV39H2 (0.45) | SUV39H2DRD2F10PIM1PIM3 | |
| SCHEMBL7235706 | 0.89 | HPGD (0.48) | SUV39H2DRD2PIM1PIM3PIM2 | |
| SCHEMBL15093029 | 0.88 | SUV39H2 (0.46) | SUV39H2DRD2PIM1PIM3PIM2 | |
| SCHEMBL2578938 | 0.88 | SUV39H2 (0.46) | SUV39H2DRD2PIM1PIM3PIM2 | |
| SCHEMBL3384005 | 0.88 | MAPT (0.48) | SUV39H2DRD2PIM1PIM3PIM2 | |
| SCHEMBL1350090 | 0.86 | SUV39H2 (0.49) | SUV39H2F10PIM1PIM3PIM2 | |
| SCHEMBL1350092 | 0.86 | SUV39H2 (0.49) | SUV39H2F10PIM1PIM3PIM2 | |
| SCHEMBL31331790 | 0.86 | DRD2 (0.45) | SUV39H2DRD2PIM1PIM3PIM2 | |
| SCHEMBL31331951 | 0.86 | DRD2 (0.45) | SUV39H2DRD2PIM1PIM3PIM2 | |
| SCHEMBL1350982 | 0.84 | SUV39H2 (0.48) | SUV39H2F10PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828991-B2 | Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MPI, TPMT | SUV39H2 2750/4885DRD2 2102/4885F10 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.